GLP-1 drugs blunt sleep apnoea in people carrying extra weight

Obstructive sleep apnoea is a highly prevalent disorder in which the upper airway repeatedly collapses during sleep, and it is strongly linked to obesity and to raised cardiovascular and metabolic risk. Three very different approaches have shown potential against it: SGLT2 inhibitors, GLP-1 receptor agonists and aerobic exercise, each working through distinct metabolic and physiological mechanisms. With GLP-1 drugs surging in use for weight, the obvious question is how these options stack up against one another. Direct comparative evidence has been scarce, which is the gap this analysis set out to fill.

The researchers searched four databases, PubMed, EMBASE, the Cochrane Library and Web of Science, for studies published before October 31, 2025, with no language restrictions. They ran a network meta-analysis, a design that lets treatments be compared indirectly through shared comparators, on 15 studies: 13 randomised controlled trials plus 2 case-control studies admitted because direct evidence was so thin. Together these covered 1,877 overweight or obese participants. The outcomes were changes in the apnoea-hypopnoea index, BMI, mean blood oxygen saturation and the Epworth Sleepiness Scale, with the certainty of every estimate formally appraised.

GLP-1 receptor agonists produced the largest reduction in the apnoea-hypopnoea index versus placebo, a mean difference of 15.28 events per hour. They also lowered BMI by 1.78 kg/m2 and raised mean oxygen saturation by 0.40%. Daytime sleepiness improved by only 0.20 points on the Epworth scale, an order of magnitude below the 2-point threshold for a clinically meaningful change, and aerobic exercise actually ranked highest for that outcome. Comparisons between the active treatments were largely non-significant, no estimate was rated high certainty, and confidence was moderate only for the BMI effect.

This is the first attempt described here to place the three approaches in a single comparative framework, and it tentatively puts GLP-1 drugs at the top for apnoea severity, weight and oxygenation. But the authors are explicit that the hierarchy is hypothesis-generating rather than a basis for firm clinical recommendations, because the between-treatment comparisons rested on indirect evidence weakened by within-study bias, imprecision and suspected reporting bias. Larger, high-quality, head-to-head trials are the stated next step, and until they exist the ranking should be held loosely.

For anyone following the GLP-1 story, this extends the drugs' plausible benefits from weight itself to a weight-linked sleep disorder, which is worth knowing given how common apnoea is among people carrying extra weight. It is equally worth noticing what did not happen: daytime sleepiness barely improved, and exercise held its own on that front. The honest reading is that GLP-1 medication looks promising for apnoea severity in this population, while the question of whether it outperforms exercise remains genuinely open.